Dr. Malte Peters to become new Chief Development Officer of MorphoSys AG

05-Jan-2017 - Germany

The Supervisory Board of MorphoSys AG has appointed Dr. Malte Peters as Chief Development Officer. Dr. Peters will take up the position on March 1, 2017 and will succeed Dr. Arndt Schottelius, who is leaving to pursue other opportunities. Dr. Peters joins MorphoSys from Sandoz, where he serves as Global Head, Clinical Development Biopharmaceuticals.

MorphoSys AG

Dr. Malte Peters

Dr. Peters built his career in early and late-stage clinical development over the last 18 years. Prior to his latest role at Sandoz, he spent 12 years in various managerial positions within Novartis focusing on management of clinical development projects in oncology. Before that, Dr. Peters served in positions as Medical Director at Micromet AG and as Head of Translational Research and Pharmacogenomics at Merck KGaA.

"Dr. Peters is an ideal addition to the Management Board of MorphoSys at this stage of the Company's growth. Drawing on his deep operational and medical experience in oncology and immunology, he will focus his efforts on the development of our clinical and pre-clinical programs, the most valuable assets driving our future growth. We look forward to welcoming him to MorphoSys." commented Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG. "We would like to thank Dr. Schottelius for his invaluable contribution over the past eight years. He has built up the development area and was instrumental in transforming MorphoSys into a credible development organization with a very promising product portfolio. We wish him the very best for the future."

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances